eISSN: 2449-9315
ISSN: 1234-8279
Pharmacotherapy in Psychiatry and Neurology/Farmakoterapia w Psychiatrii i Neurologii
Current issue Archive About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures
vol. 37
Review paper

Second generation antidepressants and the risk of arrhythmia

Julia Suwalska
Maria Napierała
Marek Proch
Iwona Szymańska
Magdalena Szydłowska
Bartosz Szablewski
Dorota Łojko

Department of Treatment of Obesity, Metabolic Disorders and Clinical Dietetics, Poznan University of Medical Sciences, Poznan, Poland
Department of Mental Health, Chair of Psychiatry, Poznan University of Medical Sciences, Poznan, Poland
HCP Medical Centre
Chair of Psychiatry, Poznan University of Medical Sciences, Poznan, Poland
Farmakoterapia w Psychiatrii i Neurologii 2021, 37 (1), 33–44
Online publish date: 2021/11/17
Article file
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
1. Bazett HC. An analysis of the time-relations of electrocardiograms. Heart 1920; 7: 353-370.
2. Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC. QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics 2013; 54(1): 1-13.
3. Beinart R, Zhang Y, Lima JA, Bluemke DA, Soliman EZ, Heckbert SR et al. The QT interval is associated with incident cardiovascular events: the MESA study. J Am Coll Cardiol 2014; 64(20): 2111-2119.
4. Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA. The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature. Psychother and Psychosom 2016; 85(5): 270-288.
5. Danielsson B, Collin J, Jonasdottir Bergman G, Borg N, Salmi P, Fastbom J. Antidepressants and antipsychotics classified with torsades de pointes arrhythmia risk and mortality in older adults - a Swedish nationwide study. Br J Clin Pharmacol 2016; 81(4): 773-783.
6. Darpö B. Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes. Eur Heart J Supplements 2001; 3 (Suppl K): K70-K80.
7. Drew BJ, Ackerman MJ, Funk M, Gibler WB, P. Kligfield, V. Menon et al. Acute Cardiac Care Committee of the Council on Clinical Cardiology tCoCN, et al: Prevention of Torsade de Pointes in Hospital Settings: A Scientific Statement From the American Heart Association and the American College of Cardiology Foundation. Circulation 2010; 121(8): 1047-1060.
8. Fanoe S, Kristensen D, Fink-Jensen A, Jensen HK, Toft E, Nielsen J et al. Risk of arrhythmia induced by psychotropic medications: a proposal for clinical management. Eur Heart J 2014; 35(20): 1306-1315.
9. Flugelman MY, Pollack S, Hammerman H. Congenital prolongation of Q-T interval: a family study of three generations. Cardiology 1982; 69.
10. Funk MC, Beach SR, Bostwick JR, Celano CM, Hasnain M, Pandurangi A et al. QTc Prolongation and Psychotropic Medications. Am J Psychiatry 2020; 177(3):273-274.
11. Girardin F, Sztajzel J. Cardiac adverse reactions associated with psychotropic drugs. Dialogues Clin Neurosci 2007; 9(1): 92.
12. Glassman A. Clinical management of cardiovascular risks during treatment with psychotropic drugs. J Clin Psychiatry 2002; 63 Suppl 9: 12-17.
13. Goldenberg I, Moss AJ Zareba W. QT interval: how to measure it and what is “normal”. J Cardiovasc Electrophysiol 2006; 17(3): 333-336.
14. Hasnain M, Vieweg WV. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review. CNS Drugs 2014; 28(10): 887-920.
15. Kasper S. Choosing among second-generation antidepressant treatments for depressed patients with cardiac diseases. Int J Psychiatry Clin Pract 2019; 23(2): 134-148.
16. Kosydar-Piechna M. Leki przeciwpsychotyczne a odstęp QT. Forum Med Rodz 2010; 4(3): 194-203.
17. Malik M. Is there a physiologic QT/RR relationship? J Cardiovasc Electrophysiol 2002; 13(12): 1219-21.
18. Nachimuthu S, Assar MD Schussler JM. Drug-induced QT interval prolongation: mechanisms and clinical management. Ther Adv Drug Saf 2012; 3(5): 241-253.
19. Nielsen J, Graff C, Kanters JK. Assessing QT interval prolongation and its associated risks with antipsychotics. CNS Drugs 2011; 25(6): 473-70.
20. Ojero-Senard A, Benevent J, Bondon-Guitton E, Durrieu G, Chebane L, Araujo M et al. A comparative study of QT prolongation with serotonin reuptake inhibitors. Psychopharmacology 2017; 234(20): 3075-3081.
21. Pawlak JM, Twarowska-Hauser JW. Poradnictwo genetyczne i farmakogenetyczne w psychiatrii. Farmakoter Psychiat Neurol 2020; 36(3): 239-249.
22. Pratt LA, Brody DJ Gu Q. Antidepressant Use Among Persons Aged 12 and Over: United States, 2011-2014. NCHS Data Brief 2017; 283: 1-8.
23. Ray WA, Chung CP, Murray KT. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360(3): 225-235.
24. Rochester MP, Kane AM, Linnebur SA, Fixen DR. Evaluating the risk of QTc prolongation associated with antidepressant use in older adults: a review of the evidence. Ther Adv Drug Saf 2018; 9(6): 297-308.
25. Sarganas G, Garbe E, Klimpel A, Hering RC, Bronder E, Haverkamp W. Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany. Europace 2014; 16(1): 101-108.
26. Schwartz PJ, Woosley RL. Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes. J Am Coll Cardiol 2016; 67(13): 1639-1650.
27. Sicouri S, Antzelevitch C. Mechanisms Underlying the Actions of Antidepressant and Antipsychotic Drugs That Cause Sudden Cardiac Arrest. Arrhythm Electrophysiol Rev 2018; 7(3): 199-209.
28. Stella F, Loureiro JC, Pais MV, Canineu PR Forlenza OV. Safety Limits of Antidepressant Use Plus Combinations: Focus on Cardiovascular Function. Curr Drug Metab 2018; 19(8): 641-652.
29. Stöllberger C, Huber JO Finsterer J. Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol 2005; 20(5): 243-251.
30. Straus SM, Kors A, De Bruin ML, van der Hooft CS, Hofman A, Heeringa J et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol 2006; 47(2): 362-367.
31. Taylor DM. Antipsychotics and QT prolongation. Acta Psychiatr Scand 2003; 107(2): 85-95.
32. Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Can Pharm J 2016; 149(3): 139- 152.
33. Tisdale JE, Jaynes HA, Kingery JR, Mourad NA, Trujillo TN. Overholser BR et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes 2013; 6(4): 479-487.
34. Trinkley KE, Page RL, Lien H, Yamanouye K, Tisdale JE. QT Interval Prolongation and the Risk of Torsades de Pointes: Essentials for Clinicians. Curr Med Res Opin 2013; 29(12): 1719-26.
35. Viskin S. The QT interval: too long, too short or just right. Heart rhythm 2009; 6(5): 711-715.
36. Viskin S, Justo D, Halkin A. Long QT syndrome caused by noncardiac drugs. Prog Cardiovasc Dis 2003; 45(5): 415-427.
37. Welch R, Chue P. Antipsychotic agents and QT changes. J Psychiatry Neurosci 2000; 25(2): 154-160.
38. Woosley RL, Black K, Heise CW Romero K. CredibleMeds. org: What does it offer? Trends Cardiovasc Med 2018; 28(2): 94-99.
39. Zaręba W. Polekowe wydłużenie odstępu QT. Folia Cardiologica 2008; 3(2): 52-73.
Quick links
© 2022 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.